Oncternal Therapeutics Inc. (NASDAQ: ONCT)
$7.40
-0.2700 ( -3.52% ) 8.2K
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Market Data
Open
$7.40
Previous close
$7.67
Volume
8.2K
Market cap
$21.61M
Day range
$7.30 - $7.49
52 week range
$5.57 - $13.14
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Aug 10, 2023 |
10-q | Quarterly Reports | 59 | Aug 10, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |